"We are pleased by the wonderful clinical results of our Phase 2 post-operative acute pain study," said Thomas A. Schreck, chairman and chief executive officer of AcelRx Pharmaceuticals. "This is the culmination of a great deal of hard work by a team of efficient, dedicated people over the last two years, and is therefore very gratifying indeed. This trial has the benefit of validating Sublingual Sufentanil NanoTabs as a robust product candidate for its initial in-hospital acute pain indication, as well as providing the foundation of safety and efficacy for the other programs in our pipeline."
About ARX-01 Sublingual Sufentanil NanoTabs
Sufentanil is currently approved as an intravenous (IV) anesthetic and is also indicated for epidural administration during labor and delivery. Due to their small size, ARX-01 Sublingual Sufentanil NanoTabs are convenient, well-tolerated, have high bioavailability and provide lower peak plasma levels compared to IV administration.
About the ARX-01 Oral Patient-Controlled Analgesia System
The ARX-01 Oral Patient-Controlled Analgesia (PCA) system is based on a
proprietary pre-programmed, hand-held dispenser being developed by AcelRx.
The AcelRx d
|SOURCE AcelRx Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved